Nasdaq:US$13.02 (-0.38) | HKEX:HK$20.65 (-0.65) | AIM:£2.20 (+0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer